May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Randomized Double-Masked Study Comparing Ranibzumab Monotherapy and PDT Combined With Ranibizumab in Patients With Exudative AMD: BCVA and Morphological Results
Author Affiliations & Notes
  • K. B. Hatz
    University Eye Hospital Basel, University Basel, Basel, Switzerland
  • U. Schneider
    University Eye Hospital Basel, University Basel, Basel, Switzerland
  • S. Sacu
    Universitaetsklinik für Augenheilkunde und Optometrie, University Wien, Wien, Austria
  • B. Henrich
    University Eye Hospital Basel, University Basel, Basel, Switzerland
  • B. Braun
    University Eye Hospital Basel, University Basel, Basel, Switzerland
  • G. Fuchsjaeger
    Universitaetsklinik für Augenheilkunde und Optometrie, University Wien, Wien, Austria
  • C. F. Pruente
    Universitaetsklinik für Augenheilkunde und Optometrie, University Wien, Wien, Austria
  • Footnotes
    Commercial Relationships  K.B. Hatz, Novartis Switzerland, F; U. Schneider, Novartis Switzerland, F; S. Sacu, None; B. Henrich, Novartis Switzerland, F; B. Braun, Novartis Switzerland, F; G. Fuchsjaeger, Novartis, F; C.F. Pruente, Novartis Switzerland, Alcon, Carl Zeiss Meditec, F.
  • Footnotes
    Support  supported in part by Novartis
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 1170. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      K. B. Hatz, U. Schneider, S. Sacu, B. Henrich, B. Braun, G. Fuchsjaeger, C. F. Pruente; Randomized Double-Masked Study Comparing Ranibzumab Monotherapy and PDT Combined With Ranibizumab in Patients With Exudative AMD: BCVA and Morphological Results. Invest. Ophthalmol. Vis. Sci. 2008;49(13):1170. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To investigate the safety and efficacy of intravitreal ranibizumab monotherapy compared to intravitreal ranibizumab combined with verteporfin photodynamic therapy (PDT) in all subtypes of CNV due to AMD.

Methods: : In this 1-year, phase III, monocenter, randomized, double-masked study, patients (n=40) received 3 monthly intravitreal ranibizumab (0.3mg) injections combined with either PDT (n=19) or sham PDT (n=21) at baseline. Thereafter, ranibizumab injections were repeated if disease progression was detectable based on loss >5 ETDRS letters relating to the best measured BCVA or increase of central retinal thickness by >100µm at OCT.

Results: : Mean BCVA was 52.1 letters in both groups. At 6 months BCVA significantly increased in both groups - by 11.8 in monotherapy and 7.8 letters in combination group (difference between groups not significant). Mean lesion size (fluoresceine angiography) at baseline was 9.38mm2 in monotherapy and 8.20mm2 in combination group. Mean proportion of leakage area/total area was 59.16% and 59.95%, respectively. At 6 months it significantly decreased to 10.32% and 5.67%, respectively (difference between groups not significant). 56% of monotherapy and 82% of combination patients did not show any angiographic activity at 6 months. Mean central retinal thickness at baseline was 324µm and 293µm, respectively. It significantly decreased to 231µm and 213µm (difference between groups not significant). Intraretinal edema was found by OCT in 33% and 18%, respectively, (baseline 100%), subretinal fluid in 33% and 18% (baseline 81% / 68%); pigment epithelial detachment in 28% and 12% (baseline 19% / 32%). In both groups intraretinal edema and subretinal fluid were significantly reduced.

Conclusions: : There was a non significant trend for less beneficial BCVA outcomes in the combination group, particularly during the first 2 months following the initial treatment. Both treatments significantly reduced mean proportion of leakage area/total area, central retinal thickness, intraretinal edema and subretinal fluid while pigment epithelial detachment was slightly increased in monotherapy group and decreased in combination group. There was a non significant trend for the combination therapy to be more efficient in reducing lesion activity at 6 months. This may explain the significantly reduced need for re-treatment in the combination group (results shown elsewhere).

Clinical Trial: : www.clinicaltrials.gov NCT00429962

Keywords: age-related macular degeneration • vascular endothelial growth factor • photodynamic therapy 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×